Authors:
Turner, SD
Wijnhoven, SWP
Tinwell, H
Lashford, LS
Rafferty, JA
Ashby, J
Vrieling, H
Fairbairn, LJ
Citation: Sd. Turner et al., Assays to predict the genotoxicity of the chromosomal mutagen etoposide - focussing on the best assay, MUT RES-GTE, 493(1-2), 2001, pp. 139-147
Authors:
Fairbairn, LJ
Chinnasamy, N
Lashford, LS
Chinnasamy, D
Rafferty, JA
Citation: Lj. Fairbairn et al., Enhancing hemopoietic drug resistance: A rationale for reconsidering the clinical use of mitozolomide, CANC GENE T, 7(2), 2000, pp. 233-239
Authors:
Turner, SD
Rafferty, JA
Fairbairn, LJ
Ashby, J
Tinwell, H
Eckert, HG
Baum, C
Lashford, LS
Citation: Sd. Turner et al., The effects of dose, route of administration, drug scheduling and MDR-1 gene transfer on the genotoxicity of etoposide in bone marrow, LEUKEMIA, 14(10), 2000, pp. 1796-1802
Authors:
Bellantuono, I
Lashford, LS
Rafferty, JA
Fairbairn, LJ
Citation: I. Bellantuono et al., The expression of full length Gp91-Phox protein is associated with reducedamphotropic retroviral production, HAEMATOLOG, 85(5), 2000, pp. 451-457
Authors:
Jelinek, J
Rafferty, JA
Cmejla, R
Hildinger, M
Chinnasamy, D
Lashford, LS
Ostertag, W
Margison, GP
Dexter, TM
Fairbairn, LJ
Baum, C
Citation: J. Jelinek et al., A novel dual function retrovirus expressing multidrug resistance 1 and O-6-alkylguanine-DNA-alkyltransferase for engineering resistance of haemopoietic progenitor cells to multiple chemotherapeutic agents, GENE THER, 6(8), 1999, pp. 1489-1493
Authors:
Chinnasamy, N
Rafferty, JA
Lashford, LS
Chinnasamy, D
Margison, GP
Thatcher, N
Dexter, TM
Fairbairn, LJ
Citation: N. Chinnasamy et al., Protection of committed murine haemopoietic progenitors against BCNU toxicity does not predict protection of primitive, multipotent spleen colony-forming cells - implications for chemoprotective gene therapy, LEUKEMIA, 13(11), 1999, pp. 1776-1783
Authors:
Michelagnoli, MP
Lewis, IJ
Gattamaneni, HR
Bailey, CC
Lashford, LS
Citation: Mp. Michelagnoli et al., Ifosfamide/etoposide alternating with high dose methotrexate: evaluation of a chemotherapy regimen for poor-risk osteosarcoma, BR J CANC, 79(7-8), 1999, pp. 1174-1178